Mimedx (MDXG) Gains from Investment Securities (2017 - 2025)
Mimedx's (MDXG) quarterly Gains from Investment Securities came in at $7000.0 in Q1 2025, down 99.94% quarter-over-quarter from $12.2 million in Q3 2017.
Powered by 
Analysis
Mimedx (MDXG) Gains from Investment Securities (2017 - 2025) Analysis & Trends
Mimedx has disclosed Gains from Investment Securities across 2 years of filings, most recently posting $7000.0 for Q1 2025.
- In Q1 2025, Gains from Investment Securities changed N/A year-over-year to $7000.0; the TTM figure through Sep 2017 stood at $12.2 million (changed N/A YoY), while the FY2017 annual figure was -$3.6 million, down 109.41% from the prior year.
- Gains from Investment Securities came in at $7000.0 for Q1 2025 at Mimedx, down from $12.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $7000.0 in Q1 2025 to a low of $7000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.74 Bn | 175.14 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.56 Bn | 122.34 Bn | 1.96 Bn |
| 3 | Medtronic | 116.90 Bn | 108.08 Bn | 6.34 Bn |
| 4 | Stryker | 103.85 Bn | 100.37 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.70 Bn | 63.16 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.88 Bn | 45.63 Bn | 1.35 Bn |
| 7 | Alcon | 33.04 Bn | 31.59 Bn | 1.68 Bn |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn |
| 9 | Steris | 20.65 Bn | 20.17 Bn | 684.20 Mn |
| 10 | Mimedx | 670.99 Mn | 535.15 Mn | 44.38 Mn |